| 臺大學術典藏 |
2021-04-27T08:11:48Z |
Anti-PD-1 immunotherapy in advanced esophageal squamous cell carcinoma: A long-awaited breakthrough finally arrives
|
HUNG-YANG KUO; Guo J.-C.; Hsu C.-H. |
| 臺大學術典藏 |
2021-04-23T05:56:30Z |
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
|
De Bono J.;Lin C.-C.;Chen L.-T.;Corral J.;Michalarea V.;Rihawi K.;Ong M.;Lee J.-H.;Hsu C.-H.;Chih-Hsin Yang;Shiah H.-S.;Yen C.-J.;Anthoney A.;Jove M.;Buschke S.;Fuertig R.;Schmid U.;Goeldner R.-G.;Strelkowa N.;Huang D.C.-L.;Bogenrieder T.;Twelves C.;Cheng A.-L.; de Bono J.; Lin C.-C.; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; Lee J.-H.; Hsu C.-H.; CHIH-HSIN YANG; Shiah H.-S.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Strelkowa N.; Huang D.C.-L.; Bogenrieder T.; Twelves C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-04-20T03:45:59Z |
Oil-in-water emulsion adjuvants for pediatric influenza vaccines: a systematic review and meta-analysis
|
Lin Y.-J.;Wen C.-N.;Lin Y.-Y.;Hsieh W.-C.;Chang C.-C.;Chen Y.-H.;Hsu C.-H.;Shih Y.-J.;Chen C.-H.;Chi-Tai Fang; Lin Y.-J.; Wen C.-N.; Lin Y.-Y.; Hsieh W.-C.; Chang C.-C.; Chen Y.-H.; Hsu C.-H.; Shih Y.-J.; Chen C.-H.; CHI-TAI FANG |
| 臺大學術典藏 |
2021-04-08T01:25:44Z |
A voxel-based partial volume correction in nuclear medicine
|
HSUAN-MING HUANG; Hsiao I.-T.; Wietholt C.; Hsu C.-H. |
| 臺大學術典藏 |
2021-03-29T05:55:47Z |
Virtual Network Embedding with Dynamic Speed Switching Orchestration in Fog/Edge Network
|
Chiang, Y.; Chao, Y.-H.; Hsu, C.-H.; Chou, C.-T.; Wei, H.-Y.; CHUN-TING CHOU |
| 臺大學術典藏 |
2021-03-19T06:57:53Z |
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment
|
Lin Z.-Z.; Hsu C.; YEUN-CHUNG CHANG; Yu C.-J.; Hsu C.-H.; Lin C.-C.; Cheng A.-L.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2021-03-19T01:54:21Z |
Modified CLIP with objective liver reserve assessment retains prognosis prediction for patients with advanced hepatocellular carcinoma
|
Shao Y.-Y.; TSUNG-HAO LIU; Lee Y.-H.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-19T01:54:20Z |
Considerations of heterogeneity in clinical trials for hepatocellular carcinoma
|
TSUNG-HAO LIU; Shao Y.-Y.; Lu L.-C.; Shen Y.-C.; Hsu C.; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-19T01:54:20Z |
Successful Hepatic Arterial Infusion of Chemotherapy in a Patient with Advanced Hepatocellular Carcinoma and Impending Liver Failure
|
TSUNG-HAO LIU; Hsu C.-H.; Shao Y.-Y. |
| 臺大學術典藏 |
2021-03-19T01:54:20Z |
Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment
|
Lu L.-C.; Lee Y.-H.; Chang C.-J.; Shun C.-T.; Fang C.-Y.; Shao Y.-Y.; TSUNG-HAO LIU; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2021-03-19T01:54:19Z |
Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma
|
Shao Y.-Y.; TSUNG-HAO LIU; Hsu C.; Lu L.-C.; Shen Y.-C.; Lin Z.-Z.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2021-03-19T01:54:19Z |
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
|
Lu L.-C.; Hsu C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; Guo J.-C.; TSUNG-HAO LIU; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-19T01:54:17Z |
It takes two to tango: breakthrough advanced hepatocellular carcinoma treatment that combines anti-angiogenesis and immune checkpoint blockade
|
TSUNG-HAO LIU; Shao Y.-Y.; Hsu C.-H. |
| 臺大學術典藏 |
2021-03-18T08:54:37Z |
Comparative study between endoscopic ultrasonography and positron emission tomography-computed tomography in staging patients with esophageal squamous cell carcinoma
|
Yen T.-J.; Chung C.-S.; YEN-WEN WU; Yen R.-F.; Cheng M.-F.; Lee J.-M.; Hsu C.-H.; Chang Y.-L.; Wang H.-P. |
| 臺大學術典藏 |
2021-03-18T08:54:23Z |
TSOC-HFrEF registry: A registry of hospitalized patients with decompensated systolic heart failure: Description of population and management
|
Wang C.-C.; Chang H.-Y.; Yin W.-H.; YEN-WEN WU; Chu P.-H.; Wu C.-C.; Hsu C.-H.; Wen M.-S.; Voon W.-C.; Lin W.-S.; Huang J.-L.; Chen S.-M.; Yang N.-I.; Chang H.-C.; Chang K.-C.; Sung S.-H.; Shyu K.-G.; Lin J.-L.; Mar G.-Y.; Chan K.-C.; Kuo J.-Y.; Wang J.-H.; Chen Z.-C.; Tseng W.-K.; Cherng W.-J. |
| 臺大學術典藏 |
2021-03-18T08:54:21Z |
The Obesity-Mortality Paradox in Patients With Heart Failure in Taiwan and a Collaborative Meta-Analysis for East Asian Patients
|
Lin G.-M.; Li Y.-H.; Yin W.-H.; YEN-WEN WU; Chu P.-H.; Wu C.-C.; Hsu C.-H.; Wen M.-S.; Voon W.-C.; Wang C.-C.; Yeh S.-J.; Lin W.-S.; Chan K.-C.; Chang H.-C.; Chang K.-C.; Chen Z.-C.; Chen S.-M.; Chu P.-H.; Hsu C.-H.; Huang J.-L.; Kuo J.Y.; Lin J.-L.; Lin W.-S.; Mar G.-Y.; Shyu K.-G.; Sung S.-H.; Tseng W.-K.; Voon W.-C.; Wang J.-H.; Wen M.-S.; Yang N.-I. |
| 臺大學術典藏 |
2021-03-18T08:54:18Z |
One-year outcomes of acute decompensated systolic heart failure in Taiwan: Lessons from TSOC-HFreF registry
|
Chang H.-Y.; Wang C.-C.; YEN-WEN WU; Chu P.-H.; Wu C.-C.; Hsu C.-H.; Wen M.-S.; Voon W.-C.; Lin W.-S.; Huang J.-L.; Chen S.-M.; Yang N.-I.; Chang H.-C.; Chang K.-C.; Sung S.-H.; Shyu K.-G.; Lin J.-L.; Mar G.-Y.; Chan K.-C.; Kuo J.-Y.; Wang J.-H.; Chen Z.-C.; Tseng W.-K.; Cherng W.-J.; Yin W.-H. |
| 臺大學術典藏 |
2021-03-18T05:58:55Z |
Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma
|
Huang T.-C.; Lin C.-C.; Wu Y.-C.; Chia-Hsien Cheng J.; Lee J.-M.; Wang H.-P.; Huang P.-M.; Hsu F.-M.; Yeh K.-H.; Cheng A.-L.; KAI-YUAN TZEN; Hsu C.-H. |
| 臺大學術典藏 |
2021-03-18T03:23:38Z |
Prognostic factors of metastatic or recurrent esophageal squamous cell carcinoma in patients receiving three-drug combination chemotherapy
|
WEI-WU CHEN; Lin C.-C.; Huang T.-C.; Cheng A.-L.; Yeh K.-H.; Hsu C.-H. |
| 臺大學術典藏 |
2021-03-18T03:23:30Z |
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
|
Lee J.-H.; WEI-WU CHEN; Hsu C.-H.; Yen Y.-H.; Yang J.C.-H.; Cheng A.-L.; Sasaki S.-I.; Chiu L.Y.; Sugihara M.; Ishizuka T.; Oguma T.; Tajima N.; Lin C.-C. |
| 臺大學術典藏 |
2021-03-18T02:03:00Z |
Disseminated peritoneal leiomyomatosis responds to systemic chemotherapy
|
Lin Y.-C.; Wei L.-H.; CHIA-TUNG SHUN; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2021-03-18T02:02:53Z |
Polymorphism in epidermal growth factor receptor intron 1 predicts prognosis of patients with esophageal cancer after chemoradiation and surgery
|
Lee J.-M.;Yang S.-Y.;Yang P.-W.;Chia-Tung Shun;Wu M.-T.;Hsu C.-H.;Lin C.-C.;Cheng J.-C.-H.;Wang Y.-H.;Chuang T.-H.;Chen J.-S.;Hsu H.-H.;Huang P.-M.;Kuo S.-W.;Lee Y.-C.; Lee J.-M.; Yang S.-Y.; Yang P.-W.; CHIA-TUNG SHUN; Wu M.-T.; Hsu C.-H.; Lin C.-C.; Cheng J.-C.-H.; Wang Y.-H.; Chuang T.-H.; Chen J.-S.; Hsu H.-H.; Huang P.-M.; Kuo S.-W.; Lee Y.-C. |
| 臺大學術典藏 |
2021-03-18T02:02:48Z |
Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study
|
Hsu C.-H.;Kang Y.K.;Yang T.-S.;Chia-Tung Shun;Shao Y.-Y.;Su W.-C.;Sandoval-Tan J.;Chiou T.-J.;Jin K.;Hsu C.;Cheng A.-L.; Hsu C.-H.; Kang Y.K.; Yang T.-S.; CHIA-TUNG SHUN; Shao Y.-Y.; Su W.-C.; Sandoval-Tan J.; Chiou T.-J.; Jin K.; Hsu C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-18T02:02:23Z |
Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment
|
Lu L.-C.;Lee Y.-H.;Chang C.-J.;Chia-Tung Shun;Fang C.-Y.;Shao Y.-Y.;Liu T.-H.;Cheng A.-L.;Hsu C.-H.; Lu L.-C.; Lee Y.-H.; Chang C.-J.; CHIA-TUNG SHUN; Fang C.-Y.; Shao Y.-Y.; Liu T.-H.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2021-03-15T08:26:16Z |
AlGaN/GaN high electron mobility transistors for protein-peptide binding affinity study
|
Huang C.-C.; Lee G.-Y.; Chyi J.-I.; HUI-TENG CHENG; Hsu C.-P.; Hsu Y.-R.; Hsu C.-H.; Huang Y.-F.; Sun Y.-C.; Chen C.-C.; Li S.-S.; Andrew Yeh J.; Yao D.-J.; Ren F.; Wang Y.-L. |
| 臺大學術典藏 |
2021-03-15T07:44:49Z |
Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer
|
LI-CHUN LU; Shao Y.-Y.; Hsu C.-H.; Hsu C.; Cheng W.-F.; Lin Y.-L.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2021-03-15T07:44:49Z |
Increasing incidence of brain metastasis in patients with advanced Hepatocellular carcinoma in the era of Antiangiogenic targeted therapy
|
Shao Y.-Y.; LI-CHUN LU; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2021-03-15T07:44:49Z |
Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems
|
Shao Y.-Y.; LI-CHUN LU; Lin Z.-Z.; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-15T07:44:48Z |
�]-Catenin (CTNNB1) mutations are not associated with prognosis in advanced hepatocellular carcinoma
|
LI-CHUN LU; Shao Y.-Y.; Lee Y.-H.; Hsieh M.-S.; Hsiao C.-H.; Lin H.-H.; Kao H.-F.; Ma Y.-Y.; Yen F.-C.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2021-03-15T07:44:48Z |
Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinoma
|
LI-CHUN LU; Shao Y.-Y.; Kuo R.N.C.; Lin Z.-Z.; Yeh Y.-C.; Shau W.-Y.; Hsu C.-H.; Cheng A.-L.; Lai M.-S. |
| 臺大學術典藏 |
2021-03-15T07:44:47Z |
Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy
|
Shao Y.-Y.; Wu C.-H.; LI-CHUN LU; Chan S.-Y.; Ma Y.-Y.; Yen F.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-15T07:44:47Z |
Clinical characteristics of advanced hepatocellular carcinoma patients with prolonged survival in the era of anti-angiogenic targeted-therapy
|
LI-CHUN LU; Shao Y.-Y.; Chan S.-Y.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-15T07:44:46Z |
Tumor heterogeneity in hepatocellular carcinoma: Facing the challenges
|
LI-CHUN LU; Hsu C.-H.; Hsu C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-15T07:44:46Z |
Tumor-associated neutrophils: An emerging player in the immune microenvironment of hepatocellular carcinoma
|
LI-CHUN LU; Hsu C.-H. |
| 臺大學術典藏 |
2021-03-15T07:44:46Z |
Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: A meta-analysis of randomized clinical trials
|
Shao Y.-Y.; Shau W.-Y.; Chan S.-Y.; LI-CHUN LU; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-15T07:44:45Z |
Prescription patterns of sorafenib and outcomes of patients with advanced hepatocellular carcinoma: A national population study
|
Li-Chun Lu;Chen P.-J.;Yeh Y.-C.;Hsu C.-H.;Chen H.-M.;Lai M.-S.;Shao Y.-Y.;Cheng A.-L.; LI-CHUN LU; Chen P.-J.; Yeh Y.-C.; Hsu C.-H.; Chen H.-M.; Lai M.-S.; Shao Y.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-15T07:44:45Z |
Inhibition of the Wnt/�]-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma
|
Lin H.-H.; Feng W.-C.; LI-CHUN LU; Shao Y.-Y.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-15T07:44:44Z |
Targeting tumor-infiltrating Ly6G+ myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinoma
|
Chang C.-J.;Yang Y.-H.;Chiu C.-J.;Li-Chun Lu;Liao C.-C.;Liang C.-W.;Hsu C.-H.;Cheng A.-L.; Chang C.-J.; Yang Y.-H.; Chiu C.-J.; LI-CHUN LU; Liao C.-C.; Liang C.-W.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-15T07:44:44Z |
Considerations of heterogeneity in clinical trials for hepatocellular carcinoma
|
Liu T.-H.;Shao Y.-Y.;Li-Chun Lu;Shen Y.-C.;Hsu C.;Lin Z.-Z.;Hsu C.-H.;Cheng A.-L.; Liu T.-H.; Shao Y.-Y.; LI-CHUN LU; Shen Y.-C.; Hsu C.; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-15T07:44:44Z |
Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment
|
Li-Chun Lu;Lee Y.-H.;Chang C.-J.;Shun C.-T.;Fang C.-Y.;Shao Y.-Y.;Liu T.-H.;Cheng A.-L.;Hsu C.-H.; LI-CHUN LU; Lee Y.-H.; Chang C.-J.; Shun C.-T.; Fang C.-Y.; Shao Y.-Y.; Liu T.-H.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2021-03-15T07:44:43Z |
Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma
|
Shao Y.-Y.;Liu T.-H.;Hsu C.;Li-Chun Lu;Shen Y.-C.;Lin Z.-Z.;Cheng A.-L.;Hsu C.-H.; Shao Y.-Y.; Liu T.-H.; Hsu C.; LI-CHUN LU; Shen Y.-C.; Lin Z.-Z.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2021-03-15T07:44:43Z |
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
|
Li-Chun Lu;Hsu C.;Shao Y.-Y.;Chao Y.;Yen C.-J.;Shih I.-L.;Hung Y.-P.;Chang C.-J.;Shen Y.-C.;Guo J.-C.;Liu T.-H.;Hsu C.-H.;Cheng A.-L.; LI-CHUN LU; Hsu C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; Guo J.-C.; Liu T.-H.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-15T07:44:42Z |
Solving the deficit of cancer pain management skills by education programs
|
Shao Y.-Y.; Lin W.-Y.; Lin C.-P.; LI-CHUN LU; Hsu C.-H. |
| 臺大學術典藏 |
2021-03-15T06:27:34Z |
Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy
|
Lin Z.-Z.; Hsu C.; Hu F.-C.; Shao Y.-Y.; DWANG-YING CHANG; Yang C.-H.; Hong R.-L.; Hsu C.-H.; Chengb A.-L. |
| 臺大學術典藏 |
2021-03-11T04:29:16Z |
Prescription patterns of anti-diabetic medications and clinical outcomes in Asian patients with heart failure and diabetes mellitus
|
Chia Y.M.F.;Teng T.-H.K.;Tay W.T.;Anand I.;Macdonald M.R.;Yap J.;Chandramouli C.;Richards A.M.;Tromp J.;Ouwerkerk W.;Ling L.H.;Lam C.S.P.;Hung C.-L.;Liew H.B.;Narasimhan C.;Ngarmukos T.;Park S.W.;Reyes E.;Siswanto B.B.;Shimizu W.;Zhang S.;Fan X.;Chen K.;Wu L.;Xie Y.;Jin Q.;Ling T.;Li X.;Zhou F.;Zhou Y.;Xu D.;Zhang H.;Su Y.;Chen X.;Qin S.;Wang J.;Gong X.;Wu Z.;Yu C.M.;Sastry B.K.S.;Gopi A.;Raghu K.;Sridevi C.;Kaur D.;Naik A.;Parikh K.;Chandarana A.;Shah U.;Chag M.;Baxi H.;Gupta S.;Bhatia J.;Khakhkhar V.;Sankhla V.;Patel T.;Kapoor V.;Wander G.S.;Tandon R.;Chopra V.;Kumar M.;Sethi H.J.S.;Verma R.;Mittal S.;Sawhney J.;Sharma M.K.;Purayil M.P.;Tedjokusumo P.;Martanto E.;Erwinanto, Munawar M.;Pambudi J.A.;Lukito A.;Pardede I.;Thengker A.;Damay V.;Danny S.S.;Surarso R.;Noda T.;Nakajima I.;Wada M.;Ishibashi K.;Kurita T.;Yasuoka R.;Asai K.;Murai K.;Kubota Y.;Izumi Y.;Ikeda T.;Hisatake S.;Kabuki T.;Kiuchi S.;Hagiwara N.;Suzuki A.;Suzuki T.;Hong S.K.;Lee S.;Soo L.D.;Kim D.-H.;Shim J.;Park S.-M.;Roh S.-Y.;Kim Y.H.;Kim M.;Choi J.-I.;Na J.O.;Rha S.W.;Seo H.S.;Oh D.J.;Park C.G.;Kim E.J.;Joung B.;Uhm J.-S.;Lee M.H.;Cho I.-J.;Park H.-N.;Park H.-W.;Cho J.-G.;Yoon N.;Lee K.;Kim K.H.;Kim S.H.;Saharudin S.;Beh B.C.;Lee Y.W.;Yen C.H.;Othman M.K.;Augustine A.-A.;Asnawi M.H.M.;Mojolou R.A.;Tan Y.Z.;Arbain A.N.;Wong C.K.;Omar R.;Ghazi A.M.;Khelae S.K.;Chew D.S.P.;Yap L.B.;Hussin A.;Muhammad Z.;Azmee M.G.;Abidin I.Z.;Zhudi A.S.B.M.;Sari N.A.M.;Sridhar G.S.;Zuhdi A.S.M.;Ismail M.D.;Ong T.K.;Cham Y.L.;Khiew N.Z.;Said A.B.;Fong A.Y.Y.;Amin N.H.M.;Seng K.C.;Tan S.K.;Yew K.L.;Santos J.;Lim A.;Lapitan R.;Andal R.;Lopez E.;Sim K.L.D.;Tan B.Y.;Lim C.P.;Teo L.L.Y.;Chan L.L.H.;Chai P.;Wong C.C.R.;Poh K.K.;Yeo P.S.D.;Lee E.M.;Loh S.Y.;Ching M.E.;Khoo D.Z.L.;Yew M.S.;Huang W.;Leong K.T.G.;See J.H.J.;Lim Y.B.;Tan S.;Yeo C.;Chai S.C.;Jaufeerally F.R.;Tulsidas H.;Aung T.;Ong H.Y.;Ling L.F.;Soon D.K.N.;Yeh H.-I.;Kuo J.-Y.;Yen C.-H.;Hwang J.-J.;Chien K.-L.;Su T.-C.;Lin L.-Y.;Juang J.-M.;Lin Y.-H.;Fu-Tien Chiang;Lin J.-L.;Ho Y.-L.;Lee C.-M.;Lin P.-C.;Hung C.-S.;Chang S.-N.;Lin J.-W.;Hsu C.-N.;Yu W.-C.;Chao T.-F.;Sung S.-H.;Wang K.-L.;Leu H.-B.;Lin Y.-J.;Chang S.-L.;Huang P.-H.;Lo L.-W.;Wu C.-H.;Liang H.-Y.;Chang S.-S.;Hsiao L.-C.;Wang Y.-C.;Lu C.-R.;Wu H.-P.;Lin Y.-N.;Chen K.-W.;Lo P.-H.;Hsu C.-H.;Hsieh L.-C.;Chandavimol M.;Yingchoncharoen T.;Laothavorn P.;Tiyanon W.;Wongcharoen W.;Phrommintikul A.;On Behalf Of The Asian-Hf Investigators; Chia Y.M.F.; Teng T.-H.K.; Tay W.T.; Anand I.; MacDonald M.R.; Yap J.; Chandramouli C.; Richards A.M.; Tromp J.; Ouwerkerk W.; Ling L.H.; Lam C.S.P.; Hung C.-L.; Liew H.B.; Narasimhan C.; Ngarmukos T.; Park S.W.; Reyes E.; Siswanto B.B.; Shimizu W.; Zhang S.; Fan X.; Chen K.; Wu L.; Xie Y.; Jin Q.; Ling T.; Li X.; Zhou F.; Zhou Y.; Xu D.; Zhang H.; Su Y.; Chen X.; Qin S.; Wang J.; Gong X.; Wu Z.; Yu C.M.; Sastry B.K.S.; Gopi A.; Raghu K.; Sridevi C.; Kaur D.; Naik A.; Parikh K.; Chandarana A.; Shah U.; Chag M.; Baxi H.; Gupta S.; Bhatia J.; Khakhkhar V.; Sankhla V.; Patel T.; Kapoor V.; Wander G.S.; Tandon R.; Chopra V.; Kumar M.; Sethi H.J.S.; Verma R.; Mittal S.; Sawhney J.; Sharma M.K.; Purayil M.P.; Tedjokusumo P.; Martanto E.; Erwinanto, Munawar M.; Pambudi J.A.; Lukito A.; Pardede I.; Thengker A.; Damay V.; Danny S.S.; Surarso R.; Noda T.; Nakajima I.; Wada M.; Ishibashi K.; Kurita T.; Yasuoka R.; Asai K.; Murai K.; Kubota Y.; Izumi Y.; Ikeda T.; Hisatake S.; Kabuki T.; Kiuchi S.; Hagiwara N.; Suzuki A.; Suzuki T.; Hong S.K.; Lee S.; Soo L.D.; Kim D.-H.; Shim J.; Park S.-M.; Roh S.-Y.; Kim Y.H.; Kim M.; Choi J.-I.; Na J.O.; Rha S.W.; Seo H.S.; Oh D.J.; Park C.G.; Kim E.J.; Joung B.; Uhm J.-S.; Lee M.H.; Cho I.-J.; Park H.-N.; Park H.-W.; Cho J.-G.; Yoon N.; Lee K.; Kim K.H.; Kim S.H.; Saharudin S.; Beh B.C.; Lee Y.W.; Yen C.H.; Othman M.K.; Augustine A.-A.; Asnawi M.H.M.; Mojolou R.A.; Tan Y.Z.; Arbain A.N.; Wong C.K.; Omar R.; Ghazi A.M.; Khelae S.K.; Chew D.S.P.; Yap L.B.; Hussin A.; Muhammad Z.; Azmee M.G.; Abidin I.Z.; Zhudi A.S.B.M.; Sari N.A.M.; Sridhar G.S.; Zuhdi A.S.M.; Ismail M.D.; Ong T.K.; Cham Y.L.; Khiew N.Z.; Said A.B.; Fong A.Y.Y.; Amin N.H.M.; Seng K.C.; Tan S.K.; Yew K.L.; Santos J.; Lim A.; Lapitan R.; Andal R.; Lopez E.; Sim K.L.D.; Tan B.Y.; Lim C.P.; Teo L.L.Y.; Chan L.L.H.; Chai P.; Wong C.C.R.; Poh K.K.; Yeo P.S.D.; Lee E.M.; Loh S.Y.; Ching M.E.; Khoo D.Z.L.; Yew M.S.; Huang W.; Leong K.T.G.; See J.H.J.; Lim Y.B.; Tan S.; Yeo C.; Chai S.C.; Jaufeerally F.R.; Tulsidas H.; Aung T.; Ong H.Y.; Ling L.F.; Soon D.K.N.; Yeh H.-I.; Kuo J.-Y.; Yen C.-H.; Hwang J.-J.; Chien K.-L.; Su T.-C.; Lin L.-Y.; Juang J.-M.; Lin Y.-H.; FU-TIEN CHIANG; Lin J.-L.; Ho Y.-L.; Lee C.-M.; Lin P.-C.; Hung C.-S.; Chang S.-N.; Lin J.-W.; Hsu C.-N.; Yu W.-C.; Chao T.-F.; Sung S.-H.; Wang K.-L.; Leu H.-B.; Lin Y.-J.; Chang S.-L.; Huang P.-H.; Lo L.-W.; Wu C.-H.; Liang H.-Y.; Chang S.-S.; Hsiao L.-C.; Wang Y.-C.; Lu C.-R.; Wu H.-P.; Lin Y.-N.; Chen K.-W.; Lo P.-H.; Hsu C.-H.; Hsieh L.-C.; Chandavimol M.; Yingchoncharoen T.; Laothavorn P.; Tiyanon W.; Wongcharoen W.; Phrommintikul A.; on behalf of the ASIAN-HF Investigators |
| 臺大學術典藏 |
2021-03-10T05:34:20Z |
Weekly 24-hour infusional 5-fluorouracil as initial treatment for advanced gastric cancer with acute disseminated intravascular coagulation
|
Ta-Chen Huang; Yeh K.-H.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2021-03-10T05:34:20Z |
Phase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus leucovorin as first-line treatment of advanced breast cancer
|
Yeh K.H.; Lu Y.S.; Hsu C.H.; Lin J.F.; Chao H.J.; Ta-Chen Huang; Chung C.Y.; Chang C.S.; Yang C.H.; Cheng A.L. |
| 臺大學術典藏 |
2021-03-10T05:34:19Z |
Systematic review and network meta-analysis: Neoadjuvant chemoradiotherapy for locoregional esophageal cancer
|
Ta-Chen Huang; Hsu C.-H.; Lin C.-C.; Tu Y.-K. |
| 臺大學術典藏 |
2021-03-10T05:34:19Z |
Prognostic factors of metastatic or recurrent esophageal squamous cell carcinoma in patients receiving three-drug combination chemotherapy
|
Chen W.-W.; Lin C.-C.; Ta-Chen Huang; Cheng A.-L.; Yeh K.-H.; Hsu C.-H. |
| 臺大學術典藏 |
2021-03-10T05:34:19Z |
Postchemoradiotherapy pathologic stage classified by the American joint committee on the cancer staging system predicts prognosis of patients with locally advanced esophageal squamous cell carcinoma
|
Guo J.-C.; Ta-Chen Huang; Lin C.-C.; Hsieh M.-S.; Chang C.-H.; Huang P.-M.; Lee J.-M.; Hsu F.-M.; Cheng J.C.-H.; Wang H.-P.; Yeh K.-H.; Cheng A.-L.; Hsu C.-H. |
